Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Derazantinib in Advanced Solid Tumors with FGFR Alterations
NCT01752920Phase 2Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Dec 2012
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of derazantinib in solid tumor, intrahepatic cholangiocarcinoma (ICC), sponsored by Basilea Pharmaceutica. Started Dec 2012; status: completed.
02
Drugs
derazantinib
03
Conditions
solid tumorintrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT01752920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01752920.